Dr. Melena Dawn Bellin, MD

Dr. Bellin practices at Fairview Clinics Specialty in Saint Paul, Minnesota.

Dr. Bellin's NPI, 1124219043, was assigned on August 6, 2007. Dr. Bellin graduated from University Of Minnesota Medical School in 2003. Dr. Bellin holds Michigan license 47172.

Dr. Bellin's primary practice is Fairview Clinics Specialty, at 1700 University W Ave, Saint Paul, MN 55104 in Ramsey County. The practice phone is (612) 672-6740.

Dr. Bellin's primary practice is Fairview Clinics Specialty in Saint Paul, Minnesota. Dr. Bellin is also affiliated with M Health Fairview University of Minnesota Medical Center. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Bellin to 4 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bellin practices. Vendor and product names are available with a free account.

Pediatric endocrinology is Dr. Bellin's primary specialty in the NPI Registry, under taxonomy code 2080P0205X. Dr. Bellin is board certified in pediatric endocrinology by the American Board of Pediatrics. Dmand AI has Dr. Bellin's licenses on file in 3 states: Michigan, Minnesota and Wisconsin.

CMS data shows 20 Medicare services from Dr. Bellin across 1 procedure code in 2023, all of them office visits, for 15 Medicare patients. Medicare paid $2,082 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 15 Medicare patients who saw Dr. Bellin in 2024. 75% of them have diabetes. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bellin's median patient age at 23, with 56% women.

In 2024, Dr. Bellin wrote 330 Medicare Part D claims for 27 patients. 45% of them were for generic drugs. CMS names the drug for 225 of them, across 8 drugs with 11 or more claims each, at $164,130 in total drug cost. In 2023, CMS named 165 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Bellin for performance year 2024, reported as part of a group. Dr. Bellin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bellin as offering telehealth.

Dmand AI links 244 papers to Dr. Bellin, published from 2008 to 2025. 2020 was the busiest year, with 23. The most frequent topics are Islets of Langerhans Transplantation, Pancreatectomy and Pancreatitis, Chronic. Dr. Bellin has published most often in Pancreas. Dr. Bellin's most frequent co-authors are Gregory J. Beilman, MD, Sarah Jane Schwarzenberg, MD and Martin L. Freeman, MD.

Dmand AI links Dr. Bellin to 9 clinical trials, 2 of them phase 2/3 studies. 2 are still active or recruiting. Conditions studied include Pancreatitis, Pancreatitis, Chronic and Diabetes Mellitus, Type 1. University of Minnesota sponsors the most, 5.

CMS Open Payments shows 96 general payments to Dr. Bellin from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. Vertex Pharmaceuticals Incorporated paid the most, $47,966. It also lists 13 research payments totaling $7,022 from 2016 to 2019.

Dmand AI lists 1 award for Dr. Bellin, most recently CMS Stage 1 EHR in 2013.

Dr. Bellin graduated from University Of Minnesota Medical School in 2003.

Dr. Bellin is in network with 18 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.